HopeStage
Back to all studies
RecruitingNCT05832489

Brain responses to methylphenidate in adult ADHD and mood-related attention difficulties

About this titleRead the official source — NCT05832489
Medication studyAges 18–60France
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 60 years.

What will I do during this study?

Participants in each group complete two MRI (magnetic resonance imaging) and EEG (recording of the brain’s electrical activity) imaging sessions in a crossover design, receiving methylphenidate before one session and placebo (an inactive comparison treatment) before the other. The study includes adults with ADHD (attention deficit hyperactivity disorder), adults with attention difficulties associated with mood conditions, and healthy controls.

Listed locations
StrasbourgSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: February 26, 2024
Recruitment status
Recruiting
Enrollment listed in the registry
80
Sponsor
University Hospital, Strasbourg, France
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
France
Age range
From 18 Years to 60 Years
Official registry ID
NCT05832489
Official title
Show the full official title

EEG-MRI Study of the Effect of Methylphenidate on Neural Mechanisms in Adult Patients With ADHD With or Without Mood Disorders: a Randomized Controlled Trial Versus Placebo

Recruitment & locations

Currently recruiting

Strasbourg

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University Hospital, Strasbourg, France, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Placebo and Methylphenidate immediate release 25mg.

Who can participate?

Listed age limits: 18 years to 60 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies